BHVN
Biohaven Ltd. Health Care Pharmaceutical Preparations Russell 3000
$15.42Close
$2.0BMarket cap
$7.79 – $17.3952-week range
Late-januaryNext report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
11%
1wk
up 11.1%
price change
1mo
up 15.5%
price change
12-month return
down 11%
market up 11% ·
its own down 26%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
39.3×
price / book
Earnings yield
down 36.2%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 311%
return on equity
Free cash margin
—
-$610.2M FCF
D/E
4.59
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
7.1%
$1.10 a day · 2×ATR $13.22
RS
78 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
1.24
50 sessions
Implied move
—
no scheduled report
Contractions
3
35% → 29% → 17%
Pivot
$16.54
6.8% below
Volume dry-up
1.5×
10 vs 50 sessions
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 31.2% over the year, from 101m to 133m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Oct 29, 2026
Last shock
Sep 10, 2026-15% in one session3.1× volumeon an SEC filing+21% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$114.5M | -$218.9M | -$567.9M | -$436.1M | -$885.1M | -$745.4M |
| Net income | -$118.7M | -$213.8M | -$570.3M | -$408.2M | -$846.4M | -$738.8M |
| Earnings per share | -$3.01 | -$5.43 | -$12.75 | -$5.73 | -$9.28 | -$6.86 |
| Free cash flow | -$77.1M | -$146.8M | -$303.8M | -$334.8M | -$586.5M | -$610.2M |
| Cash | $82.5M | $76.1M | $204.9M | $248.4M | $99.1M | $230.0M |
| Long-term debt | — | — | — | — | $0 | $238.9M |
| Shareholders' equity | $16.8M | $34.7M | $538.8M | $428.0M | $423.4M | $52.1M |
| Shares outstanding | — | 0 | 68.19m | 81.12m | 101.22m | 132.78m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 4, 2026 | Quarterly ↗ | Mar 31, 2026 | 34d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 3, 2025 | Annual ↗ | Dec 31, 2024 | 62d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results ↗ |
| Oct 22, 2026 | Regulation FD ↗ |
| Oct 15, 2026 | Material agreement · Regulation FD ↗ |
| Sep 10, 2026 | Other events ↗ |
| Aug 26, 2026 | Material agreement · Regulation FD ↗ |
| Aug 10, 2026 | Results ↗ |
| Aug 7, 2026 | Director or officer change ↗ |
| Jul 9, 2026 | Director or officer change ↗ |
| May 27, 2026 | Regulation FD ↗ |
| May 5, 2026 | Other events ↗ |
| May 4, 2026 | Results ↗ |
| May 4, 2026 | Shareholder vote ↗ |